ProfileGDS4814 / ILMN_1751396
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 10% 3% 8% 17% 4% 5% 4% 8% 27% 6% 7% 3% 2% 2% 41% 1% 16% 1% 23% 3% 14% 1% 11% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)41.199310
GSM780708Untreated after 4 days (C2_1)38.27963
GSM780709Untreated after 4 days (C3_1)40.71318
GSM780719Untreated after 4 days (C1_2)42.983217
GSM780720Untreated after 4 days (C2_2)38.70564
GSM780721Untreated after 4 days (C3_2)39.6175
GSM780710Trastuzumab treated after 4 days (T1_1)38.68234
GSM780711Trastuzumab treated after 4 days (T2_1)40.60348
GSM780712Trastuzumab treated after 4 days (T3_1)45.041727
GSM780722Trastuzumab treated after 4 days (T1_2)39.72636
GSM780723Trastuzumab treated after 4 days (T2_2)40.13267
GSM780724Trastuzumab treated after 4 days (T3_2)37.99883
GSM780713Pertuzumab treated after 4 days (P1_1)37.232
GSM780714Pertuzumab treated after 4 days (P2_1)37.15512
GSM780715Pertuzumab treated after 4 days (P3_1)47.943441
GSM780725Pertuzumab treated after 4 days (P1_2)34.54091
GSM780726Pertuzumab treated after 4 days (P2_2)42.617616
GSM780727Pertuzumab treated after 4 days (P3_2)36.28711
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)44.181923
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)38.0333
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)42.169514
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)36.00231
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)41.329411